189 related articles for article (PubMed ID: 24001942)
1. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
2. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
4. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib in the treatment of non--small-cell lung cancer.
Rothschild SI; Gautschi O
Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
8. A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.
Dikopf A; Wood K; Salgia R
Expert Opin Drug Saf; 2015 Mar; 14(3):485-93. PubMed ID: 25659177
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
10. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
[No Abstract] [Full Text] [Related]
11. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib-induced fatal fulminant liver failure.
van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
[TBL] [Abstract][Full Text] [Related]
14. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
Asai N; Yamaguchi E; Kubo A
Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
[No Abstract] [Full Text] [Related]
15. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of crizotinib inhibiting specific molecular pathways in non-small-cell lung carcinoma.
Mirshahidi HR; Mirshahidi S
Expert Rev Anticancer Ther; 2015 Apr; 15(4):375-85. PubMed ID: 25797684
[TBL] [Abstract][Full Text] [Related]
19. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.
Brosnan EM; Weickhardt AJ; Lu X; Maxon DA; BarĂ³n AE; Chonchol M; Camidge DR
Cancer; 2014 Mar; 120(5):664-74. PubMed ID: 24258622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]